Michigan Outpatient Vascular Institute on Cutting Edge of Peripheral Vascular Treatment Options

Michigan Outpatient Vascular Institute, (Dearborn Michigan) recently became the first center in the state of Michigan to enroll subjects in the clinical trial (MIMICS-2) of an investigational nitinol stent for femoropopliteal artery disease (BioMimics 3D). Elias H. Kassab, MD, FACC, FSCAI, principal investigator, headed the research team. 
Michigan Outpatient Vascular Institute (MOVI) is home to a multi-specialty endovascular practice, specializing in the diagnosis and treatment of peripheral vascular disease. It is estimated that 25 million people in the United States have peripheral arterial disease (PAD), most of which remain undiagnosed.
Call 313-359-8300 to see if you qualify to be a part of the MIMICS-2 study.

BioMimics 3D Stent. MIMICS-2 is a prospective, single-arm, multicenter clinical trial of the BioMimics 3D Stent System that is being conducted under U.S. Investigational Device Exemption (IDE) approved by FDA, which will enroll 280 subjects in up to 40 sites in the U.S. and Germany. The U.S. Principal Investigator is Timothy Sullivan, MD, Chairman of Vascular/Endovascular Surgery at Minneapolis Heart Institute at Abbott Northwestern Hospital. The European Principal Investigator is Professor Thomas Zeller of Universitäts-Herzzentrum Freiburg in Bad Krozingen, Germany. 

The purpose of MIMICS-2 is to provide data to support a US Premarket Approval Application (PMA). The trial will evaluate the BioMimics 3D Stent System against the performance goals defined by VIVA Physicians, Inc. for the safety and effectiveness of nitinol stents used in the treatment of symptomatic disease of the femoropopliteal artery.